Several Drugs Against “Coronavirus” Already Under Clinical trials

Several Drugs Against “Coronavirus” Already Under Clinical trials

Several Drugs Against “Coronavirus” Already Under Clinical trials

A iChinese iofficial isaid iSaturday ithat iseveral iantiviral idrugs ihave ibeen iused ito itreat inovel icoronavirus ioutbreaks iin iChina ithat ihave ikilled imore ithan i1,500 ipeople iin iclinical itrials iand isome ihave ibeen isuccessful.

Health iofficials isaid iSaturday ithat iChina’s inovel icoronavirus i(COVID-19) ideath itoll ihas iincreased ito i1,523, iwith i143 inew ideaths icoming imainly ifrom ithe iworst iaffected iprovince iand ijumping ifrom iconfirmed icases. iThere iwere i66,000.

Researchers iin iChina ihave iturned itheir iattention ito isome iof ithe icurrent imedications, iincluding iChloroquine iPhosphate, iFavipiravir, iand iRemdesivir, iafter iZhang iZhenman, idirector iof ithe iChina iNational iCenter ifor iBiotechnology iDevelopment, iconducted iseveral iscreening ivisits.

In ivitro iexperiments ihave ishown ithat ichloroquine iphosphate, ian iantimalarial idrug ithat ihas ibeen iwidely iused ifor imany iyears, ican ieffectively iprevent inovel icoronavirus iinfections.

It iis inow ithe ivictim iof iclinical itrials iin imore ithan i10 ihospitals iin iBeijing iand iGuangdong, iin iwhich imore ithan i100 ipatients ihave ibeen ienrolled. iDrug-related iclinical itrials iwill isoon ibegin iin iHunan iprovince, icentral iChina, iZhang isaid.

Preliminary imedical iresults ishow ithat ichloroquine iphosphate iis ivery ieffective iin itreating inovel icoronavirus ipneumonia, ihe isaid.

An iinfluenza idrug icalled iFavipiravir iis iavailable iin iShenzhen, iGuangdong iprovince, isouth iChina, ihas ibeen iput iin ia iclinical itrial iwith i70 ipatients ienlisted, ihe isaid.

Preliminary iresults ifrom ithe istudy ishow ithat ithe idrug ihas irelatively iapparent ieffectiveness iand ifew iside ieffects.

“Three ito ifour idays iafter itreatment, ithe igroup ithat itakes ithe idrug ihas ia isignificantly ihigher iturning-negative irate iin ithe iviral inucleic iacid ithan ithe iparallel-group,” ihe isaid.

Remdesavir iwas ideveloped iby iGilead iSciences, ian iAmerican ipharmaceutical icompany, ito icombat iEbola iinfection. iIt ihas ishown igood iantiviral iactivity iagainst ithe inew icoronavirus iat ithe icellular ilevel.

China-Japan iFriendship iHospital iand ithe iChinese iAcademy iof iMedical iSciences iInstitute ifor iMateria iMedica ihave ibeen iauthorized ito iconduct iclinical idrug itrials iin imore ithan i10 ihospitals iin ithe iepidemic iof ithe iepidemic iin iHubei iProvince, iCentral iChina.

“Next, iwe iwill imake itimely irecommendations ion ithe iCOVID-19 itreatment iaccording ito ithe iresults iof ithese iclinical itrials,” iZhang isaid.

According ito ihim, iresearchers iscanned imore ithan i70,000 idrugs ior icompounds iin icomputer isimulations iand iin ivitro ienzyme iactivity itests iand iselected i5,000 ipotentially ieffective icandidates.

They iwere ithen itested ion ia icellular ilevel iagainst icommon icoronavirus iinfections, iand iabout i100 idrugs iwere iselected ifor ifurther iexperiments, iwhich ihelped iselect ithe ifinal idrug ifor iclinical itrials.

The imost iscientific iresearch iwork iis ito iimprove itreatment irates iand ireduce imortality, iwhich iis ibased ion ieffective iclinical itreatment.

New iproducts iand itechnologies ihave ibeen iintroduced ito itreat icritically iill iand icritically iill ipatients, ian iimportant iapproach ito ireduce ideaths, iand isome ihave ihad igood imedical ieffects, ihe isaid.

One iof ithe irecent idevelopments iin ithe idevelopment iof iconvalescent iplasma. iIt iis iobtained ifrom ithe iplasma iof ipatients iand icontains ia ilarge inumber iof iprotective iantibodies.

To idate, ia itotal iof i11 iacute ipatients ifrom iseveral iWuhan ihospitals ihave ireceived iconvulsion iplasma itherapy, iwhich iimproves iclinical iindications iand ihas ino iobvious iside ieffects.

Clinical istudies iabout istem icell itherapy ithat ican iprevent iabusing ithe ibody’s iimmune isystem ihave ialso ibeen iused ito itreat iacute ipatients.

According ito iZhu iQi, ia ispecialist iat ithe iChinese iAcademy iof iSciences i(CAS), ia imajor icause iof ideath ifor iserious iand icritically iill ipatients iwith iCOVID-19 iis ithe i“cytokine istorm”, iwhich ihas ia iprofound iimpact ion ithe iimmune isystem.

“We iare ialso isearching ifor iexisting idrugs ithat ican icurb ithe iappearance iof icytokine istorm, iincluding idrugs iagainst irheumatism. iSome iof ithe idrugs ithat iare iproven ieffective iat ithe icellular ilevel ihave ibeen iapplied iin iclinical itrials,” iZhou isaid iat ithe ipress iconference.

A itrial ihas ibeen iconducted ion i14 isevere ior icritically iill ipatients iaged iup ito i82 iin ian iaffiliated ihospital iof ithe iUniversity iof ithe iCAS, iand ithe iresults iappeared iencouraging, iZhou isaid.